RO4917523
Sponsors
Hoffmann-La Roche
Conditions
DepressionFragile X SyndromeHealthy Volunteer
Phase 1
A Study of the Ability of Functional Magnetic Resonance Imaging (fMRI) to Detect and Characterize the Effects of Two Marketed Centrally Active Drugs, Placebo, and RO4917523 in Healthy Volunteers
CompletedNCT01045083
Start: 2010-01-31End: 2011-06-30Updated: 2016-11-02
A Pharmacokinetic Study of RO4917523 in Healthy Japanese and Caucasian Subjects
CompletedNCT01368926
Start: 2011-06-30End: 2011-11-30Updated: 2016-11-02
A Human Proof of Concept Study for [11C]-RO5011232 as Radiotracer and Study of the Binding of RO4917523 to Human mGlu5 Brain Receptor at Steady-State in Healthy Volunteers
CompletedNCT01483469
Start: 2011-12-31End: 2013-10-31Updated: 2016-11-02
A Study of The Excretion Balance, Pharmacokinetics and Metabolism of A Single Oral Dose of [14C]-Labeled RO4917523 in Healthy Male Volunteers
CompletedNCT01592890
Start: 2012-04-30End: 2012-05-31Updated: 2016-11-02
A Study of the Effect of Carbamazepine on the Pharmacokinetics of RO4917523 in Healthy Volunteers
CompletedNCT01629368
Start: 2012-06-30End: 2012-09-30Updated: 2016-11-02
A Study of the Effect of Fluvoxamine on the Pharmacokinetics of RO4917523 in Healthy Volunteers
CompletedNCT01665404
Start: 2012-07-31End: 2012-09-30Updated: 2016-11-02
A Study of Three Modified-Release Formulations of RO4917523 in Healthy Volunteers
CompletedNCT01873508
Start: 2013-06-30End: 2013-08-31Updated: 2015-09-10
Phase 2
A Study of RO4917523 in Patients With Treatment Resistant Depression
CompletedNCT00809562
Start: 2009-03-31End: 2011-02-28Updated: 2016-11-02
A Study With RO4917523 in Patients With Fragile X Syndrome
CompletedNCT01015430
Start: 2009-11-30End: 2011-01-31Updated: 2016-11-02
A Study of RO4917523 in Pediatric Patients With Fragile X Syndrome
CompletedNCT01750957
Start: 2013-02-28End: 2014-04-30Updated: 2016-08-11